Skip to main content

Vedanta Biosciences Granted First European Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia

 

Clinical courses

Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, announced that the European Patent Office (EPO) has issued European Patent EP2575835. The patent broadly covers pharmaceutical compositions of Clostridium live bacterial strains and further expands Vedanta Biosciences’ patent portfolio after the issuances of three U.S. patents in the previous months and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.

The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta Biosciences. Dr. Honda’s work provides an avenue for the treatment of a variety of diseases including immune and infectious diseases employing bacterial strains belonging to Clostridium clusters IV and/or XIVa. Clostridium bacteria include a variety of spore-forming species that can abundantly colonize the gut.

“This European patent is an important addition to our global intellectual property portfolio,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. “The claims issued put Vedanta in a very favorable position to commercialize drugs based on bacterial consortia in the second largest market in the world.” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email